v3.26.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
6 Months Ended
Jun. 30, 2026
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES  
Schedule of research and development expenses

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three months ended June 30, 

​

Six months ended June 30, 

​

  ​ ​ ​

2026

  ​ ​ ​

2025

  ​ ​ ​

2026

  ​ ​ ​

2025

External clinical development expenses

​

$

2,475,836

​

$

1,637,683

​

$

4,959,301

​

$

3,334,914

Personnel related and stock-based compensation

​

 

1,027,495

​

 

258,072

​

 

1,749,752

​

 

687,490

Other research and development expenses

​

 

123,837

​

 

154,830

​

 

351,877

​

 

402,320

Total research and development expenses

​

$

3,627,168

​

$

2,050,585

​

$

7,060,930

​

$

4,424,724